Low-dose naltrexone inhibits pemoline-induced self-biting behavior in prepubertal rats

Area of Science:

• Neuroscience
• Pharmacology
• Behavioral Science

Background:

• Self-injurious behavior (SIB) is observed in mental retardation syndromes and autism.
• Opiate antagonists like naltrexone have shown success in treating SIB clinically.
• Pemoline-induced self-biting behavior in rats serves as an animal model for SIB.

Purpose of the Study:

• To investigate the effect of naltrexone on pemoline-induced self-biting behavior in an animal model.
• To explore the dose-dependent efficacy of naltrexone in reducing SIB.
• To compare findings in the animal model with clinical observations of naltrexone treatment for SIB.

Main Methods:

• Administered varying subcutaneous doses of naltrexone (0.01-10 mg/kg) to rats exhibiting pemoline-induced self-biting behavior.
• Quantified the severity of self-biting behavior at different naltrexone dosages.
• Reviewed existing clinical data on naltrexone's efficacy in treating SIB.

Main Results:

• A low dose of naltrexone (0.01 mg/kg) significantly reduced self-biting behavior.
• Higher doses of naltrexone (0.10-10 mg/kg) did not show a significant effect on self-biting behavior.
• Clinical data suggests a similar therapeutic window for naltrexone in treating human SIB.

Conclusions:

• Naltrexone's efficacy in reducing SIB appears mediated by mu-opioid receptor interactions.
• Loss of efficacy at higher doses may be due to kappa-opioid receptor binding.
• Opioid-dopamine interactions might play a role in pemoline-induced self-biting behavior.